| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8453653 | Lung Cancer | 2018 | 12 Pages |
Abstract
Erlotinib plus bevacizumab enhances OS for EGFR-mutant patients, with rash and diarrhea common but acceptable adverse effects. Combination treatment can be recommended as the preferable option for EGFR-mutant patients. Further large-scale, well-designed RCTs are required to confirm our validation.
Keywords
EGFR-TKIRCTsECoGPRISMAKRASORRProsperoFDAAesPFsRandomized controlled trialsAdverse effectsErlotinibProgression free survivaloverall survivalbevacizumabInternational Prospective Register of Systematic ReviewsRelative riskTargeted therapyFood and Drug AdministrationNSCLCNon-small cell lung cancereastern cooperative oncology groupconfidence intervalsVascular Endothelial Growth Factor (VEGF)Meta-analysisEpidermal growth factor receptor tyrosine kinase inhibitorobjective response ratehazard ratioKirsten Rat Sarcoma
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Binghao Zhao, Wenxiong Zhang, Dongliang Yu, Jianjun Xu, Yiping Wei,